Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Somatrogon is a long-acting recombinant human growth hormone approved in several countries, including Japan, for the treatment of children with growth hormone deficiency (GHD).

The primary endpoints of the OLE included annualized height velocity (HV), change in height standard deviation score (SDS), and safety.

Who Took Part

The study group was 43 patients.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the patients and staff both knew the treatment.

What Was Measured

The primary endpoints of the OLE included annualized height velocity (HV), change in height standard deviation score (SDS), and safety.

PubMed files the paper under topics including Human Growth Hormone, Japan, Body Height, Growth Disorders, Dwarfism, Pituitary and East Asian People.

The authors tagged it with the keywords Growth hormone deficiency, Long-acting growth hormone, Somatrogon and Somatropin.

What This Means in Plain Language

The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 43 patients.

The publication is from 2026 (Endocrine journal), a journal based in Japan.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.